About naxitamab gqgk
Anti-GD2 monoclonal antibody
Used for
- Used with GM-CSF for high-risk neuroblastoma in bone or bone marrow that has not responded to treatment or has returned.
Usual adult dose
20 mg/m² intravenously on days 1, 3, and 5 of each treatment cycle, with GM-CSF; dose is capped at 70 mg per infusion.
Usual dose in children
20 mg/m² intravenously on days 1, 3, and 5 of each treatment cycle, with GM-CSF; dose is capped at 70 mg per infusion.
Common side effects
- Pain
- Infusion reactions, including allergic reactions
- Low blood pressure
- Fever and low blood-cell counts
Important warnings
- Can cause severe infusion reactions, including anaphylaxis.
- Can cause severe pain during infusion.
- Can cause low blood pressure and neurological problems.
- Treatment requires monitoring and medicines to prevent or manage reactions.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for two months afterward.
Breastfeeding
It is not known whether this medicine passes into breast milk. Breastfeeding is not recommended during treatment and for two months afterward.
Interactions
- No well-established drug interactions are listed; treatment includes GM-CSF and medicines to prevent infusion reactions.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.